cannabidiol
Associations Comment on the Nomination of Robert M. Califf for FDA Commissioner
On Nov. 12, President Biden announced that he will nominate Robert M. Califf, MD for commissioner of the U.S. Food and Drug Administration (FDA). Califf is an internationally recognized expert in clinical trial research, health disparities, health care quality and cardiovascular medicine. He has nearly four decades of experience as a doctor, researcher, leader and ...
CRN Applauds President Biden’s Intent to Nominate Robert M. Califf for FDA Commissioner
The Council for Responsible Nutrition (CRN) applauded President Joe Biden’s apparent intent to nominate Robert M. Califf, MD, for Commissioner of the U.S. Food and Drug Administration (FDA). According to CRN’s President and CEO, Steve Mister, “CRN welcomes the news of President Biden’s apparent intent to nominate Dr. Robert M. Califf to lead FDA as ...
AHPA Updates Proposition 65 Hemp Industry Guidance Following Passage of California AB 45
The American Herbal Products Association (AHPA) has published an update to its Guidance on California Proposition 65 and Hemp Products to recognize the impact of the passage of California AB 45 Industrial hemp products, which was signed into law by Governor Gavin Newsome on October 6, 2021. The AHPA document provided guidance to the hemp industry about ...
AHPA Submits Comments to “Cannabis Administration and Opportunity Act” Discussion Draft
On September 1, 2021, the American Herbal Products Association (AHPA) submitted comments to the Senate sponsoring offices for the “Cannabis Administration and Opportunity Act” (CAOA) Discussion Draft. In a unique approach to development of federal legislation, Sens. Chuck Schumer (D-NY), Ron Wyden (D-OR), and Corey Booker (D-NJ) released the CAOA discussion draft on July 14, ...
CRN Denounces FDA Rejection of NDI Notifications for Hemp Extract Containing CBD
The Council for Responsible Nutrition (CRN) has denounced the U.S. Food and Drug Administration’s (FDA) rejection of two new dietary ingredient (NDI) notifications for full-spectrum hemp extract containing cannabidiol (CBD)—and urged Congress to act on pending legislative proposals that require the agency to address the lack of regulation of hemp-derived products. “CRN is extremely disappointed to ...
CV Sciences and UC San Diego Publish Study of Cannabidiol Efficacy in Treating Nicotine Dependence
CV Sciences, Inc. has announced progress toward its goal of developing and commercializing a CBD-based pharmaceutical to treat nicotine addiction in smokeless tobacco users. The company, in collaboration with researchers from the University of California, San Diego (“UC San Diego”), published a preclinical study demonstrating the efficacy of chronic CBD treatment in reducing nicotine dependence ...
FDA Warns Selling of Topical CBD Products Violates FD&C Act
On March 22, the U.S. Food and Drug Administration stated that it has issued warning letters to two companies for selling topical pain relief products labeled as containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). Specifically, the warning letters addressed the illegal marketing of unapproved drugs labeled ...
Bipartisan Legislation to Regulate Hemp-derived CBD Re-introduced in Congress
On Feb. 4, 2021 Representative Kurt Schrader (D-OR) and Representative Morgan Griffith (R-VA) re-introduced bipartisan legislation that would protect public health by providing legal clarity in the cannabidiol (CBD) product marketplace. Re-introduced in the 117th Congress as HR 841, the Hemp and Hemp-derived CBD Consumer Protection and Market Stabilization Act of 2021 directs the U.S. ...
Endocannabinoid Support: Outlook 2021
The endocannabinoid system, still new in health sciences, has been the muse for CBD and other products. This area is only going to grow. Still somewhat dewy fresh in the spotlight of human biological systems, the endocannabinoid system (ECS) has been the focus of dramatic product development. After all, its existence was discovered only 30 ...
FDA Submits CBD Enforcement Guidance to White House For Review
U.S. Food and Drug Administration (FDA) has submitted draft CBD (cannabidiol) enforcement guidance to the White House Office of Management and Budget (OMB) for review, according to Marijuana Moment. The contents or even basic scope of the document titled, “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” are not yet publicly known. The agency was mandated ...
Don't Miss Out!
Industry Professionals
Stay Informed!
Stay informed about the latest health, nutrition, and wellness developments by signing up for a FREE subscription to Vitamin Retailer magazine and digital newsletter.
Once subscribed, you will receive industry insights, product trends, and important news directly to your doorstep and inbox.
Featured Listing:
Subscribe To Our Newsletter
Stay Informed! Breaking news, industry trends featured topics, and more.
Subscribe to our newsletter today!